9 completed, 1 recruiting, 1 terminated, 1 unknown. 13 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 9, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Insulinoma: new trials by email Literature Review of Insulinoma trials Research Report on Insulinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma 68Ga-NOTA-exendin-4 - Insulinoma | Phase 1 | Unknown | First Affiliated Hospital of Fujian Medical University | 60 | 2020-08-01 | 2023-09-21 |
| Laser Tissue Welding - Distal Pancreatectomy Sealing Study Distal Pancreatectomy Sealing Using LTW - Pancreatic Tumor, Benign, Pancreatic Neoplasms | Phase 1 | Completed | Laser Tissue Welding, Inc. | 11 | 2018-01-01 | 2022-04-06 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH 68Ga-NODAGA-exendin 4 PET/CT - Insulinoma | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 56 | 2015-04-01 | 2021-06-16 |
| Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma Fluorodopa F 18 - Congenital Hyperinsulinism, Insulinoma | Phase 1 | Recruiting | Cook Children's Health Care System | 250 | 2013-10-09 | 2024-07-16 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Cixutumumab, Everolimus, Laboratory Biomarker Analysis - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-10-01 | 2016-07-15 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors everolimus, vatalanib, pharmacological study - Gastrinoma, Glucagonoma | Phase 1 | Completed | Mayo Clinic | 96 | 2004-12-01 | 2024-08-21 |
| Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors 90Y-DOTA-tyr3-OCTREOTIDE - Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor | Phase 1 | Completed | O'Dorisio, M S | 27 | 2002-01-01 | 2016-06-21 |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer trastuzumab, tipifarnib - Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2000-06-01 | 2013-02-11 |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum floxuridine, leucovorin calcium, oxaliplatin - Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 2000-04-01 | 2011-04-26 | |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu recombinant interleukin-12, ABI-007/carboplatin/trastuzumab - Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 1999-08-01 | 2013-02-28 |
| Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer yttrium Y 90-edotreotide - Brain and Central Nervous System Tumors, Breast Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 60 | 1998-01-01 | 2013-05-01 |
| Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer indium In 111 pentetreotide - Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis | Phase 1 | Terminated | Yale University | 35 | 1996-10-01 | 2014-07-02 |
Glucagonoma (9) · Somatostatinoma (8) · Carcinoma, Islet Cell (7) · Gastrinoma (7) · Vipoma (7) · Carcinoma, Medullary (6) · Pheochromocytoma (5) · Adenoma, Islet Cell (4) · Carcinoma, Merkel Cell (4) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Renal Cell (4) · Neoplasms (4) · Pancreatic Neoplasms (4) · Appendiceal Neoplasms (3)
Adenoma (13) · Digestive System Diseases (13) · Digestive System Neoplasms (13) · Endocrine Gland Neoplasms (13) · Endocrine System Diseases (13) · Neoplasms by Histologic Type (13) · Neoplasms by Site (13) · Neoplasms, Glandular and Epithelial (13) · Pancreatic Diseases (13) · Adenocarcinoma (10) · Carcinoma (10) · Neoplasms, Germ Cell and Embryonal (10) · Neuroectodermal Tumors (10) · Adenoma, Islet Cell (9) · Carcinoma, Neuroendocrine (9)
Everolimus (2) · Trastuzumab (2) · 68Ga-NOTA-exendin-4 (1) · 90Y-octreotide, DOTA-Tyr(3)- (1) · Acetates (1) · Capecitabine (1) · Floxuridine (1) · High-Energy Shock Waves (1) · Interleukin-12 (1) · Interleukin-12 Subunit p35 (1) · Leucovorin (1) · Octreotide (1) · Oxaliplatin (1) · Salts (1) · Temozolomide (1)
National Cancer Institute (NCI) (3) · Cook Children's Health Care System (1) · First Affiliated Hospital of Fujian Medical University (1) · Laser Tissue Welding, Inc. (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · O'Dorisio, M S (1) · Radboud University Medical Center (1) · Vanderbilt-Ingram Cancer Center (1) · Yale University (1)
United States (10) · China (1)
Anthony W. Tolcher, MD (1) · James Yao (1) · John R. Murren, MD (1) · Jordan Berlin, M.D. (1) · Julian R. Molina, M.D., Ph.D. (1) · Larry K. Kvols, MD (1) · Leonard B. Saltz, MD (1) · M. Sue O'Dorisio, MD, PhD (1) · Martin Gotthardt, Prof. Dr. (1) · Paul Thornton, MD (1) · William Carson (1)
2014 (1), P30CA016672 (1), R44CA203052 (1), U01CA062461 (1), U01CA076576 (1)